- Home
- ELEV vs MTVA Comparison
ELEV vs MTVA Comparison
Compare ELEV & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- MTVA
- Stock Information
- Founded
- ELEV 2019
- MTVA 2014
- Country
- ELEV United States
- MTVA United States
- Employees
- ELEV N/A
- MTVA N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- ELEV Health Care
- MTVA
- Exchange
- ELEV Nasdaq
- MTVA NYSE
- Market Cap
- ELEV 18.1M
- MTVA 15.1M
- IPO Year
- ELEV 2021
- MTVA N/A
- Fundamental
- Price
- ELEV $0.32
- MTVA $0.69
- Analyst Decision
- ELEV Buy
- MTVA Strong Buy
- Analyst Count
- ELEV 6
- MTVA 2
- Target Price
- ELEV $2.94
- MTVA $7.50
- AVG Volume (30 Days)
- ELEV 753.5K
- MTVA 600.4K
- Earning Date
- ELEV 08-05-2025
- MTVA 05-14-2025
- Dividend Yield
- ELEV N/A
- MTVA N/A
- EPS Growth
- ELEV N/A
- MTVA N/A
- EPS
- ELEV N/A
- MTVA N/A
- Revenue
- ELEV N/A
- MTVA N/A
- Revenue This Year
- ELEV N/A
- MTVA N/A
- Revenue Next Year
- ELEV N/A
- MTVA N/A
- P/E Ratio
- ELEV N/A
- MTVA N/A
- Revenue Growth
- ELEV N/A
- MTVA N/A
- 52 Week Low
- ELEV $0.22
- MTVA $0.63
- 52 Week High
- ELEV $3.77
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- ELEV 49.38
- MTVA N/A
- Support Level
- ELEV $0.29
- MTVA N/A
- Resistance Level
- ELEV $0.32
- MTVA N/A
- Average True Range (ATR)
- ELEV 0.02
- MTVA 0.00
- MACD
- ELEV 0.00
- MTVA 0.00
- Stochastic Oscillator
- ELEV 59.01
- MTVA 0.00
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.